- Home
- NEO vs TNGX Comparison
NEO vs TNGX Comparison
Compare NEO & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEO | TNGX |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | NEO | TNGX |
|---|---|---|
| Price | $11.87 | $9.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $12.56 | $12.50 |
| AVG Volume (30 Days) | 1.8M | ★ 2.7M |
| Earning Date | 10-28-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $709,162,000.00 | $66,501,000.00 |
| Revenue This Year | $10.90 | $53.01 |
| Revenue Next Year | $9.88 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 10.10 | ★ 53.29 |
| 52 Week Low | $4.72 | $1.03 |
| 52 Week High | $19.12 | $11.20 |
Technical Indicators
Market Signals| Indicator | NEO | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 60.77 | 52.39 |
| Support Level | $11.59 | $8.89 |
| Resistance Level | $12.26 | $10.22 |
| Average True Range (ATR) | 0.42 | 0.63 |
| MACD | -0.07 | -0.14 |
| Stochastic Oscillator | 49.80 | 20.91 |
Price Performance
Historical ComparisonAbout NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.